KQ-2003 CAR T-cells
Phase 1Cell therapy
KQ-2003 CAR T-cells is one of 27 biologic programs targeting POEMS syndrome. It is currently in Phase 1.
2
Indications
3
Total Trials
2
Active Trials
26
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
1135 competitors in Multiple Myeloma
#DrugCompanyPhaseTrials
1Prolia
AmgenPreclinical
Eliquis
Bristol-Myers SquibbPreclinical
Adriamycin
GGynecologic Oncology Group
Preclinical
Nolvadex
AstraZenecaPreclinical
Oncovin
EEastern Cooperative Oncology Group
Preclinical
Intron a
Merck & Co.Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
Abecma
Bristol-Myers SquibbPreclinical
Oblimersen Sodium
NNational Cancer Institute (NCI)
Preclinical
Florbetaben
LLife Molecular Imaging GmbH
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Multiple Myeloma2 trials
POEMS syndrome1 trial
A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory POEMS Syndrome
Not yet recruiting·NNovatim Immune Therapeutics (Zhejiang) Co., Ltd.·Phase 1·NCT06518876·21 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for KQ-2003 CAR T-cells. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details